It is due to the 82% and it has nothign to do with FDA requirements, 82% is extensive accurate by any medical measure.
Think of today as an earnings release on in relation to analyst estimates. If the Q Numbers dont meet or beat the estimates the PPS usually plunges, even if the revenue had % increase over the last q.
And thats exactly what happened today, 90%+ results were expected and instead we got 82%. Is it a bad thing? Not at all!
I dont want to think of today as me losing money because I havent closed any of my position in the stock and I dont want to be the guy who pumps "thank you for the cheapies" but this company does have alot of good things going.
82% accuracy is unheard of within the lung cancer community, if nothing else the results make them a huge buyout target.
Market Data 
Markets 
AI
